AstraZeneca unit raises investment in Newcastle University programme

Sunday 17 May 2009

The AstraZeneca Plc subsidiary, KuDOS Pharmaceuticals Ltd, has increased its investment in a programme at Newcastle University that seeks to develop drugs inhibiting DNA-dependent protein kinase, thereby improving cancer treatments.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom